好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Efficacy of Cyclooxygenase-2 Inhibitors for Headache in Acute Brain Injury: A Systematic Review
Headache
P7 - Poster Session 7 (11:45 AM-12:45 PM)
12-006

To identify the efficacy of cyclooxygenase-2 (COX-2) inhibitors (COXIBs) for headache in acute brain injury (ABI).

Headache after ABI is common; yet, treatment options are limited and heavily rely on opioids. COX-2 is overexpressed in ABI and responsible for inducing pain. Hence, COXIBs may be a promising and potentially opioid-sparing therapeutic option for headache following ABI.

We performed a systematic review through MEDLINE and Embase databases spanning 08/2021-09/2023. Interventional and observational studies assessing headache in adult patients with ABI were included. Each article was reviewed by two independent reviewers using Distiller SR®. Data were synthesized through descriptive statistics. A meta-analysis was unfeasible due to study heterogeneity.

Of 3193 articles, 6 met inclusion criteria: 4 randomized controlled trials and 2 retrospective cohort studies, all conducted in neurosurgical patients (n=913). Five studies used COXIBs in the intervention group only; one reported reduction in overall 10-point visual analog scale (VAS) (mean±SD [3.8±0.9 vs 5.3±1.3]) and morphine use (median[range] 6[0-18] vs 10[0-40] mg); another reported reduction in 10-point VAS (mean [3.5/3.2/2.9 vs 4.2/4.0/3.6]) and morphine equivalent units (mean [1.2/0.8/1.6/4.6 vs 11.6/13.0/12.6/45.2]) at overall time intervals; one showed reduction in 100-point VAS (mean±SEM [25±3 vs 38±4]) and morphine use (mean±SEM [0.8±0.3 vs 2.7±0.8] mg) at only 1 time interval; one reported reduction in 10-point numeral pain scores (NRS) in 3 time intervals (mean [2.5/2.0/1.8 vs 3.0/2.5/2.0]) but did not assess opioid use; and one did not find any reduction in VAS or opioid use. One study which assessed dexmedetomidine and ropivacaine as adjuncts and used COXIBs in both groups, reported reduction in pain in the intervention group.

In post-neurosurgical patients, COXIBs might be a promising opioid-sparing adjunctive therapy for headache. Given the overall limited data available, evidence to establish their efficacy will require additional research including other forms of ABI.

Authors/Disclosures
Katharina M. Busl, MD, MS, FAAN (University of Florida)
PRESENTER
Dr. Busl has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Rissman Law. Dr. Busl has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Huffman Powell Baley. Dr. Busl has received personal compensation in the range of $500-$4,999 for serving as a Consultant for University Science. Dr. Busl has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for SCCM. Dr. Busl has a non-compensated relationship as a Board Member with Art in Medicine that is relevant to AAN interests or activities. Dr. Busl has a non-compensated relationship as a Associate Editor with Critical Care Explorations that is relevant to AAN interests or activities. Dr. Busl has a non-compensated relationship as a Assistant Editor with Neurocritical Care that is relevant to AAN interests or activities.
Luciola Martins Frota, MD Dr. Martins Frota has nothing to disclose.
Anum Khaliq, MD Dr. Khaliq has nothing to disclose.
Hector David Meza Comparan, MD (University of Florida) Dr. Meza Comparan has nothing to disclose.
Daniela Pomar Forero, MD (University of Florida) Ms. Pomar Forero has nothing to disclose.
Bakhtawar Ahmad, MBBS Dr. Ahmad has nothing to disclose.
Carolina B. Maciel, MD, MSCR, FAAN Dr. Maciel has received research support from American Heart Association. Dr. Maciel has received research support from National Institute of Health.